MADISON, WI, USA, Oct 31, 2019 – Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc. (Nasdaq: EXEL). Exelixis and Invenra had entered into a collaboration on May 2nd, 2018 to discover and develop multispecific antibodies through the use of Invenra’s B-Body™ technology platform. The new collaboration will continue to use the Invenra antibody discovery capabilities to generate additional biologics-based programs.
“The expanded collaboration speaks to the strength and early success of the initial collaboration between Exelixis and Invenra,” said Bonnie Hammer, Ph.D., Vice President of Research and Development of Invenra. “We are excited to continue to work with the Exelixis team. Both teams have demonstrated the desire to generate best-in-class therapeutics, and this expanded collaboration enables us to continue generating novel candidates for the Exelixis pipeline.”